THC Global Group Limited (ASX:THC) chief executive officer Ken Charteris updates Proactive on being granted a licence to manufacture therapeutic goods for the company’s Southport Facility, known as a GMP Licence, by the Australian Therapeutic Goods Administration (TGA).
This milestone completes all licences required for THC Global to commence commercial manufacture of pharmaceutical medicinal cannabis.
Production at the facility on the Gold Coast began in early December.
The company also recently signed a supply agreement with MGC Pharmaceuticals Ltd for the supply of formulated medicinal cannabis products for Australian patients and the global export market.
